MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

Title:
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Authors:
Felder, Mildred; Kapur, Arvinder; Gonzalez-Bosquet, Jesus; Horibata, Sachi; Heintz, Joseph; Albrecht, Ralph M.; Fass, Lucas; Kaur, Justanjot; Hu, Kevin; Shojaei, Hadi; Whelan, Rebecca J. ( 0000-0002-9293-1528 ) ; Patankar, Manish S.
Abstract:
Over three decades have passed since the first report on the expression of CA125 by ovarian tumors. Since that time our understanding of ovarian cancer biology has changed significantly to the point that these tumors are now classified based on molecular phenotype and not purely on histological attributes. However, CA125 continues to be, with the recent exception of HE4, the only clinically reliable diagnostic marker for ovarian cancer. Many large-scale clinical trials have been conducted or are underway to determine potential use of serum CA125 levels as a screening modality or to distinguish between benign and malignant pelvic masses. CA125 is a peptide epitope of a 3–5 million Da mucin, MUC16. Here we provide an in-depth review of the literature to highlight the importance of CA125 as a prognostic and diagnostic marker for ovarian cancer. We focus on the increasing body of literature describing the biological role of MUC16 in the progression and metastasis of ovarian tumors. Finally, we consider previous and on-going efforts to develop therapeutic approaches to eradicate ovarian tumors by targeting MUC16. Even though CA125 is a crucial marker for ovarian cancer, the exact structural definition of this antigen continues to be elusive. The importance of MUC16/CA125 in the diagnosis, progression and therapy of ovarian cancer warrants the need for in-depth research on the biochemistry and biology of this mucin. A renewed focus on MUC16 is likely to culminate in novel and more efficient strategies for the detection and treatment of ovarian cancer.
Citation:
Felder, Mildred, Arvinder Kapur, Jesus Gonzalez-Bosquet, et al. 2014. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Molecular Cancer 13(1):129.
Publisher:
Biomed Central Ltd.
DATE ISSUED:
2014-05
Department:
Chemistry and Biochemistry
Type:
Article
PUBLISHED VERSION:
10.1186/1476-4598-13-129
Additional Links:
http://www.molecular-cancer.com/content/13/1/129
PERMANENT LINK:
http://hdl.handle.net/11282/528249

Full metadata record

DC FieldValue Language
dc.contributor.authorFelder, Mildreden
dc.contributor.authorKapur, Arvinderen
dc.contributor.authorGonzalez-Bosquet, Jesusen
dc.contributor.authorHoribata, Sachien
dc.contributor.authorHeintz, Josephen
dc.contributor.authorAlbrecht, Ralph M.en
dc.contributor.authorFass, Lucasen
dc.contributor.authorKaur, Justanjoten
dc.contributor.authorHu, Kevinen
dc.contributor.authorShojaei, Hadien
dc.contributor.authorWhelan, Rebecca J.en
dc.contributor.authorPatankar, Manish S.en
dc.date.accessioned2015-04-13T13:32:19Zen
dc.date.available2015-04-13T13:32:19Zen
dc.date.issued2014-05en
dc.identifier.citationFelder, Mildred, Arvinder Kapur, Jesus Gonzalez-Bosquet, et al. 2014. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Molecular Cancer 13(1):129.en
dc.identifier.issn1476-4598en
dc.identifier.urihttp://hdl.handle.net/11282/528249en
dc.description.abstractOver three decades have passed since the first report on the expression of CA125 by ovarian tumors. Since that time our understanding of ovarian cancer biology has changed significantly to the point that these tumors are now classified based on molecular phenotype and not purely on histological attributes. However, CA125 continues to be, with the recent exception of HE4, the only clinically reliable diagnostic marker for ovarian cancer. Many large-scale clinical trials have been conducted or are underway to determine potential use of serum CA125 levels as a screening modality or to distinguish between benign and malignant pelvic masses. CA125 is a peptide epitope of a 3–5 million Da mucin, MUC16. Here we provide an in-depth review of the literature to highlight the importance of CA125 as a prognostic and diagnostic marker for ovarian cancer. We focus on the increasing body of literature describing the biological role of MUC16 in the progression and metastasis of ovarian tumors. Finally, we consider previous and on-going efforts to develop therapeutic approaches to eradicate ovarian tumors by targeting MUC16. Even though CA125 is a crucial marker for ovarian cancer, the exact structural definition of this antigen continues to be elusive. The importance of MUC16/CA125 in the diagnosis, progression and therapy of ovarian cancer warrants the need for in-depth research on the biochemistry and biology of this mucin. A renewed focus on MUC16 is likely to culminate in novel and more efficient strategies for the detection and treatment of ovarian cancer.en
dc.language.isoen_USen
dc.publisherBiomed Central Ltd.en
dc.identifier.doi10.1186/1476-4598-13-129en
dc.relation.urlhttp://www.molecular-cancer.com/content/13/1/129en
dc.subject.departmentChemistry and Biochemistryen_US
dc.titleMUC16 (CA125): tumor biomarker to cancer therapy, a work in progressen_US
dc.typeArticleen
dc.identifier.journalMolecular Canceren
dc.subject.keywordOvarian canceren_US
dc.subject.keywordCA125en_US
dc.subject.keywordMUC16en_US
dc.subject.keywordCancer biomarkeren_US
dc.subject.keywordMetastasisen_US
dc.subject.keywordImmunesupressionen_US
dc.subject.keywordNatural killer cellsen_US
dc.identifier.volume13en_US
dc.identifier.issue1en_US
dc.identifier.startpage129en_US
dc.rightsArchived with thanks to Molecular Canceren
All Items in The Five Colleges of Ohio Digital Repository are protected by copyright, with all rights reserved, unless otherwise indicated.